Medlab Clinical (ASX:MDC) - Non Executive Chairperson, Michael Hall
Non Executive Chairperson, Michael Hall
Source: Medlab Clinical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medlab Clinical (MDC) reports positive net operating cashflows for the December quarter of $645,000
  • Revenue at the half-year was $5.6 million, representing a 33 per cent growth from the previous corresponding period
  • The company spent $851,000 on research and development (R&D) during the quarter and received $3.2 million in R&D cash rebates
  • Looking ahead, the company is making progress towards its FDA application for NanaBis
  • Shares closed flat today at 12.5 cents each

Medlab Clinical (MDC) has reported positive net operating cashflows for the December quarter of $645,000.

Receipts from customers totalled $2.7 million while revenue at the half-year was $5.6 million, representing a 33 per cent growth from the previous corresponding period.

The company’s cash position at the end of the quarter was about $11.2 million.

MDC said while its market cap is below expected, its principal assets are valued well above market capitalisation.

The company spent $851,000 on research and development (R&D) during the quarter and received $3.2 million in R&D cash rebates.

It was also pre-approved for $12 million in R&D rebates for future expenses relating to its NanaBis program.

NanaBis is an investigative cannabinoid program for patients with cancer bone pain. To date, the company said it has improved patient outcomes with over 1000 Australian patients under clinical management.

Looking ahead, the company is making progress towards its Food and Drug Administration (FDA) application for NanaBis.

It is also in joint venture discussions for NanoCBD with key significant local distribution and manufacturing companies to expand availability. Under an accelerated regulatory model, NanoCBD would be approved for over-the-counter pharmacy sales. 

Shares closed flat today at 12.5 cents each.

MDC by the numbers
More From The Market Herald
Recce Pharmaceuticals (ASX:RCE) - Chief Executive Officer, James Graham

" Recce Pharmaceuticals’ (ASX:RCE) clinical trial returns positive safety profile

Recce Pharmaceuticals (ASX:RCE) has seen its clinical trial receive a good safety profile among ten healthy…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…
Grand Gulf Energy (ASX:GGE) - Managing Director, Dane Lance

" Grand Gulf Energy (ASX:GGE) sees high helium concentrations in Jesse#1A well

Grand Gulf Energy (ASX:GGE) has detected helium concentrations up to 37 times above background levels in…
Marquee Resources (ASX:MQR) - Executive Chair, Charles Thomas

" Marquee Resources (ASX:MQR) begins drilling at Kibby Basin

Marquee Resources (ASX:MQR) has begun drilling at the highly prospective Kibby Basin lithium project in Nevada,…